Valuation NewAmsterdam Pharma Company N.V. Börse Stuttgart
Stocks
KH6
NL00150012L7
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
08:04:39 2026-09-24 EDT
|
5-day change | 1st Jan Change | ||
| 19.88 EUR | +0.15% |
|
+7.44% | -32.50% |
| 08-26 | NewAmsterdam Pharma Presents Data From Obicetrapib Development Program At European Society Of Cardiology Congress 2026 | CI |
| 08-14 | Newamsterdam Pharma Company N.V. Announces Executive Changes | CI |
Company Valuation: NewAmsterdam Pharma Company N.V.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | - | 831.8 | 831.9 | 2,657 | 3,388 | 2,380 | - | - |
| Change | - | - | 0.01% | 219.43% | 27.48% | -29.76% | - | - |
| Enterprise Value (EV) 1 | - | 393.3 | 831.9 | 2,657 | 2,849 | 1,956 | 1,823 | 1,812 |
| Change | - | - | 111.52% | 219.43% | 7.22% | -31.36% | -6.79% | -0.63% |
| P/E | -3.39x | -10.6x | -5.09x | -10.2x | -20.5x | -12.1x | -12.9x | -43.7x |
| PBR | - | 1.72x | - | 3.72x | - | - | - | - |
| PEG | - | 0.2x | -0x | -0.4x | 0.5x | -1x | 2.24x | 0.6x |
| Capitalization / Revenue | - | 8.53x | 64x | 61.2x | 178x | 96.6x | 20x | 7.77x |
| EV / Revenue | - | 4.03x | 64x | 61.2x | 150x | 79.4x | 15.3x | 5.91x |
| EV / EBITDA | - | - | - | - | -14.9x | -9.2x | -120x | 8.85x |
| EV / EBIT | - | -56.5x | -4.93x | -15.8x | -14.9x | -8.98x | -9.83x | -61.4x |
| EV / FCF | - | 49.4x | -6.38x | -17.5x | -22.7x | -14.9x | -7.23x | -11.2x |
| FCF Yield | - | 2.02% | -15.7% | -5.7% | -4.4% | -6.7% | -13.8% | -8.93% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.53 | -0.96 | -1.984 | -2.438 | -1.454 | -1.639 | -1.545 | -0.4554 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 97.5 | 13.01 | 43.39 | 19.03 | 24.64 | 119.1 | 306.3 |
| EBITDA 1 | - | - | - | - | -190.6 | -212.6 | -15.14 | 204.8 |
| EBIT 1 | - | -6.96 | -168.9 | -167.9 | -190.8 | -217.8 | -185.4 | -29.51 |
| Net income 1 | -28.6 | -78.05 | -163.3 | -230.1 | -172.3 | -201.7 | -196.3 | -53.18 |
| Net Debt 1 | - | -438.5 | - | - | -538.5 | -423.7 | -556.4 | -567.9 |
| Reference price 2 | 8.57 | 10.20 | 10.11 | 24.82 | 29.88 | 19.91 | 19.91 | 19.91 |
| Nbr of stocks (in thousands) | - | 81,560 | 82,324 | 107,053 | 113,391 | 119,537 | - | - |
| Announcement Date | 8/4/22 | 3/31/23 | 2/28/24 | 2/26/25 | 2/18/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.81x | 7.74x | 15.55x | 1.36% | 74.18B | |
| 30.94x | 8.91x | 27.77x | 0.04% | 59.55B | |
| -72.24x | 13.96x | -67.31x | -.--% | 25.84B | |
| -15.16x | 5.72x | -7.19x | -.--% | 24.73B | |
| 28.65x | 5.38x | 17.91x | -.--% | 20.87B | |
| 44.32x | 16.25x | 32.97x | 0.34% | 15.32B | |
| 17.52x | 5.22x | 12.18x | -.--% | 14.06B | |
| -14.32x | 3225.89x | -16.49x | -.--% | 13.12B | |
| -81.25x | 7.42x | -61.47x | -.--% | 11.85B | |
| Average | -4.41x | 366.28x | -5.12x | 0.19% | 28.84B | |
| Weighted average by Cap. | 6.13x | 171.32x | 3.83x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NAMS Stock
- KH6 Stock
- Valuation NewAmsterdam Pharma Company N.V.
Select your edition
All financial news and data tailored to specific country editions
